BioCryst制药 BCRX 深 沪
已收盘 12-12 16:00:00 美东时间
7.57
-0.010
-0.13%
华盛通- 最 高7.82
- 今 开7.82
- 成交量 522.27万股
- 最 低 7.23
- 昨 收 7.58
- 总市值 15.97亿
- 52周最高 11.31
- 市盈率 静 --
- 换手率 2.48%
- 52周最低 6.00
- 委 比 78.61%
- 总股本 2.11亿
- 历史最高 19.99
- 量 比 1.67
- 振 幅 7.78%
- 历史最低 1.08
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Approves BioCryst's NDA For Use Of Oral Pellet Formulation Of Once-Daily ORLADEYO For Prophylactic Therapy In Pediatric Patients With Hereditary Angioedema Aged 2 To <12 Years
–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration-–Showed early and sustained reductions in
12-12 20:02
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Needham Maintains Buy on BioCryst Pharma, Lowers Price Target to $18
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $20 to $18.
11-04 18:41
BioCryst Pharma Raises FY2025 Sales Guidance from $580.000M-$600.000M to $590.000M-$600.000M vs $625.558M Est
BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to $590.000 million-$600.000 million vs $625.558 million estimate.
11-03 20:01
BioCryst Pharma Q3 Adj. EPS $0.16 Beats $0.04 Estimate, Sales $159.395M Miss $162.974M Estimate
BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.04 by 357.14 percent. This is a 328.57 percent increase over losses of $(0.07) per share from
11-03 20:00
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
BioCryst Pharmaceuticals To Present Four Abstracts From Second Interim Analysis of APeX-P Trial At Annual Scientific Meeting Of The American College Of Allergy, Asthma & Immunology In Orlando, Florida
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking
10-23 19:03
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
<p><p align="justify">BioCryst Pharmaceuticals will present four abstracts at the ACAAI meeting in November 2025, showcasing long-term prophylaxis data with ORLADEYO in pediatric HAE patients and psychosocial impact studies. ORLADEYO is the only oral therapy for HAE prevention in adults and adolescents, targeting plasma kallikrein. The study aims to evaluate safety and efficacy in younger patients. Key safety considerations include dosage adjustm...
10-23 11:00
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
